FATEbenzinga

Fate Therapeutics Wins Regenerative Medicine Advanced Therapy Designation From FDA For FT819 To Treat Moderate To Severe Systemic Lupus Erythematosus

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on April 14, 2025 by benzinga